U.S. Markets closed

Ampio Pharmaceuticals, Inc. (AMPE)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.58+0.00 (+0.24%)
At close: 4:02PM EDT

0.58 0.00 (0.00%)
After hours: 6:36PM EDT

People also watch
ANTHACRXMRNSALIMAVEO
Full screen
Previous Close0.58
Open0.59
Bid0.57 x 1000
Ask0.76 x 4200
Day's Range0.57 - 0.60
52 Week Range0.52 - 3.67
Volume750,215
Avg. Volume479,277
Market Cap39.57M
Beta0.57
PE Ratio (TTM)-2.23
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals3 months ago

    Colorado biotech's accountants express 'substantial doubt' about firm's future

    In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .

  • TheStreet.com11 months ago

    7 Stocks Under $10 That Could Make You a Lot of Money

    When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

  • Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)
    Insider Monkeylast year

    Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)

    Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has recently reported topline from its PIVOT trial and the stock lost over 60% on the announcement last Thursday. From this decline alone, it’s clear that the company didn’t report anything great, but despite missing the primary endpoint in the trial, management is shooting for an approval on the data. What […]